Curing India's import-driven $5 bn medtech industry with niche devices

Bengaluru-based Blue Neem is developing devices in nephrology, radiology and gastroenterology as it aims to make India the manufacturing hub in this segment

Pharma
Centre had a few months ago brought coronary stents and orthopaedic knee implants under price cap
Samreen Ahmad Bengaluru
Last Updated : Jun 02 2018 | 10:48 PM IST
The Indian medical devices market has traditionally been import-driven, despite the availability of inexpensive labour and local manufacturing advantages. 

When Vishnu Bhat was working at IT major Infosys in the 1990s and listening to the likes of N R Narayana Murthy talk about building the future of the nation and what every individual could mean for it, Bhat came to the conclusion that if he had to make a contribution, it had to be in the sunrise medical devices sector.

It was an underinvested, under-focussed and under-leveraged industry which never witnessed a boom like its sister, the pharmaceuticals industry.

Hence, Blue Neem came into being in 2009 with the idea of curing the import-laden medical devices industry through local manufacturing like neem which has healing properties and is native to India. It was founded by Bhat, who incubated the cloud and big data businesses at Infosys, and Pankaj Hans, Rajendra, Satish B, and Vittal Rao, all experts in the medical devices manufacturing space with over 20 years of experience.

“If you have import dependence, there is nothing much you can do on managing cost of health care, you can only pump in taxpayers’ money in the form of subsidy,” said Bhat, founder of Blue Neem. The huge mark-up cost at the distribution level make imported products cost 10 times more than locally manufactured ones.

With the motive of making India a manufacturing hub for medical devices, the 400 plus Blue Neem team is bringing innovation with risk-based management in the domestic market. 

According to KPMG,  if today’s medical device manufacturers fail to stake their claim in the evolving value chain, they risk being caught in the middle and becoming commoditised. Staying ahead means offering value beyond the device and solving healthcare’s problems – rather than contributing to them.

In India, there are over 100 medical devices companies but these are mostly commodity-driven, with lack of specialty players.

Blue Neem is trying to disrupt the ecosystem with its innovations which are exclusively made to suit the Indian anatomy. It has recently launched a urethral stent which reduces discomfort as it moves away from the sensitive area unlike the stents available in the market. Called the Triple J, it is an improvement over the Double J stents which causes discomfort to patients. 

The company is also working with the Karnataka — Israel Program for Industrial R&D to develop a device to reduce urinary incontinence among women. It’s a novel device which will go to trials soon.

Apart from urology, its team of about 10 innovators are working towards developing niche devices in the nephrology, gastroenterology, and radiology segments, including products such as catheters, needles, blood tubing sets, haemodialysis, drainage, and dilation instruments.

The over $96-billion health care industry lacks significant players in the medical devices segment due to lack of government framework. Until now only 15 devices were regulated, that too under the Drugs and Cosmetics Act. The quality of produce was self-regulated and there were a lot of grey areas.

Due to the history of an unregulated set-up, the acceptance of locally made products is weak.

But Bhat says a promising future is insight with the government set to unveil a draft Medical Device Regulation Bill for comprehensive regulation of the sector. It will consolidate laws related to medical devices and establish the Medical Device Regulatory Authority of India for maintaining a national system of controls relating to quality, safety, efficacy and availability of medical devices that are used in India.

Bhat feels with new laws being laid, the sector will have the potential to draw funding like the start-up sector. “Once we have a strong local manufacturing set-up and we are able to raise the standard in the country, these will provide an impetus to reduce the overall health care cost,” said the founder of the Bengaluru-based company. 

The company is already exporting its products to over 70 countries and expects to be a big part of India’s medical devices innovation story, a sector which is expected to swell over 10 times from the current $5 billion by 2025.
 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story